MabionCD20

MabionCD20

Products

Information

This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.
All Categories
Monoclonal Antibodies
Main Categories
Biopharmaceutical Products
Distribution Areas
North America (USA, Canada)Europe - EU countries
MabionMabion is a fully integrated CDMO providing comprehensive GMP development and manufacturing services for biotherapeutics, including monoclonal antibodies, vaccine antigens, and recombinant proteins. We offer end-to-end solutions—from cell line development and process scale-up to analytics, fill & finish, and quality control. Specialized in bispecific antibodies, ADCs, and biosimilars, Mabion partners globally with clients operating in highly regulated environments.

Log in

See all the content and easy-to-use features by logging in or registering!